MedTrace Logo

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT01419704 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-03-03

No results posted yet for this study

Summary

The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with hemoglobinopathies.

Conditions

Interventions

BIOLOGICAL

Enriched Hematopoetic Stem Cell Infusion

Enriched Hematopoetic Stem Cell Infusion

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Talaris Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne T Ildstad, MD · Talaris Therapeutics Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2016-05-31
Completion
2016-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01419704 on ClinicalTrials.gov